(Q53346443)

English

A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma.

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/16683077

A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma. (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/16683077

gastroesophageal junction adenocarcinoma

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

object named as

Jaffer A Ajani

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/16683077

author name string

Yixing Jiang

2

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/16683077

Josephine Faust

3

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/16683077

Baochong B Chang

4

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/16683077

Linus Ho

5

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/16683077

James C Yao

6

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/16683077

Steven Rousey

7

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/16683077

Shaker Dakhil

8

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/16683077

Richard C Cherny

9

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/16683077

Catherine Craig

10

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/16683077

Archie Bleyer

11

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/16683077

publication date

1 July 2006

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/16683077

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/16683077

24

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/16683077

4

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/16683077

353-357

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/16683077

The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow

1 reference

https://pubmed.ncbi.nlm.nih.gov/16683077

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Successful treatment of murine melanoma with bryostatin 1.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16683077

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/16683077

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Global cancer statistics, 2002

1 reference

https://pubmed.ncbi.nlm.nih.gov/16683077

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Protein kinase C as the receptor for the phorbol ester tumor promoters: sixth Rhoads memorial award lecture

1 reference

https://pubmed.ncbi.nlm.nih.gov/16683077

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Protein kinase C isozymes as potential targets for anticancer therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/16683077

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of leukemic cell growth by the protein kinase C activator bryostatin 1 correlates with the dephosphorylation of cyclin-dependent kinase 2

1 reference

https://pubmed.ncbi.nlm.nih.gov/16683077

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Protein kinase C and beyond

1 reference

https://pubmed.ncbi.nlm.nih.gov/16683077

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin

1 reference

https://pubmed.ncbi.nlm.nih.gov/16683077

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bryostatin 1, an activator of protein kinase C, mimics as well as inhibits biological effects of the phorbol ester TPA in vivo and in vitro

1 reference

https://pubmed.ncbi.nlm.nih.gov/16683077

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Potentiation of the activity of 1-beta-D-arabinofuranosylcytosine by the protein kinase C activator bryostatin 1 in HL-60 cells: association with enhanced fragmentation of mature DNA.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16683077

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/16683077

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of Taxol in patients with advanced gastric carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/16683077

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bryostatin 1, a unique biologic response modifier: anti-leukemic activity in vitro.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16683077

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-006-6452-1

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/16683077

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/16683077

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53346443&oldid=2212085566"